X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

CBAY

Closed

Cymabay Therapeu

32.48
+0.01 (+0.03%)
Last Update: 25 Mar 2024 16:30:00
Yesterday: 32.47
Day's Range: 32.48 - 32.48
Send
When Written:
 
8.72
Cymabay Therapeutics is a biopharmaceutical company that focuses on developing therapies for liver and other chronic diseases. The company's lead product candidate, seladelpar, is a selective peroxisome proliferator-activated receptor delta agonist that is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Seladelpar has shown promising results in clinical trials and has received Fast Track designation from the US FDA for the treatment of PBC. Cymabay Therapeutics is also developing other product candidates for the treatment of liver and other chronic diseases, including a preclinical program for the treatment of fibrotic diseases. The company is headquartered in Newark, California, USA.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.15
X